Introducing Faron
Faron Pharmaceuticals is a clinical-stage biopharmaceutical company based in Finland and the United States, with a focus on developing bexmarilimab, a first-in-class, humanized antibody that binds the Clever-1 target on myeloid cells and macrophages.
Clever-1 is an immunosuppressive receptor that promotes tumor growth and metastases when expressed on macrophages. Bexmarilimab primes the tumor microenvironment for optimal antitumor immune responses, in both hematological malignancies and solid tumors.
We continue to see impressive growth in our bexmarilimab program, with exciting early data across both hematologic malignancies and solid tumors. These accomplishments could not have been done without the continued support of our shareholders and the incredible team at Faron. We have a bright future ahead and I’d like to thank everyone for their dedication to fighting cancer and improving patient outcomes...
Dr. Markku Jalkanen,Non-Executive Director & Founder
Event Large
A rewarding career
Faron is on a mission to bring the promise of immunotherapy to a broader population. We are looking at new therapeutic approaches and novel combination therapies that could break treatment resistance and bring longer-lasting therapeutic outcomes to a greater proportion of patients.
We are a pioneer in macrophage-targeting therapies and have a novel pipeline that originates from academic discoveries and scientific findings. Faron offers a compelling career where brave thinkers and independent doers are joined.
OUR SCIENCE
Bexmarilimab is a first-in-class, humanized monoclonal antibody that binds to Clever-1, an immunosuppressive receptor found on macrophages leading to tumor growth and metastases (i.e., it helps cancer to evade the immune system), and a novel immune checkpoint target for drug development.
By targeting the Clever-1 receptor on macrophages, bexmarilimab alters the tumor microenvironment, reprogramming macrophages from an immunosuppressive (M2) state to an immunostimulatory (M1) one, upregulating interferon production and priming the immune system to attack tumors and sensitizing cancer cells to standard of care.